Clinical Trial

A new study shows Candela's Nordlys laser not only reverses skin aging at a DNA level but may also fight cancer, setting a new bar for the industry.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

A new milestone in a Parkinson's clinical trial isn't just about the science; it's about building the system to deliver a potential cure to the masses.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

New data reveals how Genelux’s oncolytic virus reawakens chemotherapy's power, offering a potential lifeline in a notoriously difficult-to-treat cancer.

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Interim data shows AC Immune's Alzheimer's candidate is safe, but a pivot to boost its power reveals a high-stakes bet on efficacy over speed.

Promising 12-month trial data for SKY-0515 shows it may halt Huntington's, a first for an oral pill. This could disrupt the neuro-market.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.

With Olav Hellebø at the helm, Exonate is advancing a topical eye drop that could end painful eye injections for millions with diabetic retinopathy.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA approval for its pivotal TRIUMPH trial, Laplace Interventional is challenging giants in the lucrative tricuspid valve market. A strategic play.

Onkos Surgical hit 500 cases with its NanoCept antibacterial coating. Is this nano-scale tech the key to winning the war on devastating surgical infections?

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

CraniUS Therapeutics secures up to $4M in NIH funding for its NeuroPASS device, a refillable implant aiming to revolutionize glioblastoma and CNS treatment.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.